Assorted news from the last week:
This year’s Cancer Grand Challenges (funded by Cancer Research UK and the National Cancer Institute) include a category for Solid Tumors in Children.
Contract Research Organization PRA Health Sciences published a white paper encouraging industry sponsors to identify, seek out, and partner with patient organizations as they try to meet the demands of the RACE for Children Act.
OncoHeroes BioSciences announced that its therapeutic Volasertib received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) to treat pediatric rhabdomyosarcoma and other rare soft tissue sarcomas.
Cooking up Change launched this video and a new website that demand better environmental policies from elected officials for a less toxic environment that could reduce the incidence of cancer in children. It also highlights the work of organizations and initiatives (like the Childhood Cancer Prevention Initiative) that are making that change happen.
Upcoming webinars and Online Opportunities:
Clouds centering on the life of Zach Sobiech debuts on Disney+ on Oct. 16. Read the back story and get CAC2 Member Laura Sobiech’s perspective on making the movie of Zach’s life, and view the trailer.
Neuroblastoma Parent Global Symposium on November 6th and 7th, 2020 offers a free, online, 2-day event that will bring together families directly affected by neuroblastoma around the world with those who work to treat, help and support them. Researchers and clinicians will lead sessions to provide information on current treatments around the world and share emerging therapies. Registration is now open to reserve a space for this free event!
SIOP 2019 Webcasts are now available online for free.
- CAC2 Childhood Cancer Community News Digest (September 26-October 2)
- CAC2 Childhood Cancer Community News Digest (September 19-25)
- CAC2 Childhood Cancer Community News Digest (September 12-18)
- CAC2 Childhood Cancer Community News Digest (August 29-September 11)
- Guest Blog–National Cancer Institute’s CCDI Molecular Characterization Initiative Adds Rare Tumors